

Russell D Cohen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5322224/publications.pdf>

Version: 2024-02-01

104
papers

6,440
citations

101384

36
h-index

66788

78
g-index

106
all docs

106
docs citations

106
times ranked

5076
citing authors

#	ARTICLE	IF	CITATIONS
1	Serious Infections and Mortality in Association With Therapies for Crohn's Disease: TREAT Registry. <i>Clinical Gastroenterology and Hepatology</i> , 2006, 4, 621-630.	2.4	831
2	Serious Infection and Mortality in Patients With Crohn's Disease: More Than 5 Years of Follow-Up in the TREAT Registry. <i>American Journal of Gastroenterology</i> , 2012, 107, 1409-1422.	0.2	652
3	Prevalence of nonadherence with maintenance mesalamine in quiescent ulcerative colitis. <i>American Journal of Gastroenterology</i> , 2001, 96, 2929-2933.	0.2	384
4	Intravenous Cyclosporin in Ulcerative Colitis: A Five-Year Experience. <i>American Journal of Gastroenterology</i> , 1999, 94, 1587-1592.	0.2	317
5	An Open-Label Study of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects with Prior Loss of Response or Intolerance to Infliximab for Crohn's Disease. <i>American Journal of Gastroenterology</i> , 2004, 99, 1984-1989.	0.2	249
6	A Meta-Analysis and Overview of The Literature on Treatment Options for Left-Sided Ulcerative Colitis and Ulcerative Proctitis. <i>American Journal of Gastroenterology</i> , 2000, 95, 1263-1276.	0.2	244
7	Are dysplasia and colorectal cancer endoscopically visible in patients with ulcerative colitis?. <i>Gastrointestinal Endoscopy</i> , 2007, 65, 998-1004.	0.5	237
8	Infliximab in Crohn's Disease: First Anniversary Clinical Experience. <i>American Journal of Gastroenterology</i> , 2000, 95, 3469-3477.	0.2	207
9	Absence of Infliximab in Infants and Breast Milk From Nursing Mothers Receiving Therapy for Crohn's Disease Before and After Delivery. <i>Journal of Clinical Gastroenterology</i> , 2009, 43, 613-616.	1.1	145
10	Pregnancy and Neonatal Outcomes After Fetal Exposure to Biologics and Thiopurines Among Women With Inflammatory Bowel Disease. <i>Gastroenterology</i> , 2021, 160, 1131-1139.	0.6	145
11	Complete response of metastatic melanoma in a patient with Crohn's disease simultaneously receiving anti-IL27 and anti-PD1 antibodies. , 2019, 7, 1.		143
12	The Cost of Hospitalization in Crohn's Disease. <i>American Journal of Gastroenterology</i> , 2000, 95, 524-530.	0.2	128
13	Autoimmune disease concomitance among inflammatory bowel disease patients in the United States, 2001-2002. <i>Inflammatory Bowel Diseases</i> , 2008, 14, 738-743.	0.9	122
14	Open-label study of adalimumab in patients with ulcerative colitis including those with prior loss of response or intolerance to infliximab. <i>Inflammatory Bowel Diseases</i> , 2009, 15, 1302-1307.	0.9	113
15	Infliximab Decreases Resource Use Among Patients With Crohn's Disease. <i>Journal of Clinical Gastroenterology</i> , 2002, 35, 151-156.	1.1	106
16	Medical management of left-sided ulcerative colitis and ulcerative proctitis: Critical evaluation of therapeutic trials. <i>Inflammatory Bowel Diseases</i> , 2006, 12, 979-994.	0.9	97
17	Use of Biologic Therapy by Pregnant Women With Inflammatory Bowel Disease Does Not Affect Infant Response to Vaccines. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 99-105.	2.4	97
18	Co-occurrence and comorbidities in patients with immune-mediated inflammatory disorders: an exploration using US healthcare claims data, 2001-2002. <i>Current Medical Research and Opinion</i> , 2006, 22, 989-1000.	0.9	95

#	ARTICLE	IF	CITATIONS
19	Side-to-Side Isoperistaltic Strictureplasty in Extensive Crohn's Disease. <i>Annals of Surgery</i> , 2000, 232, 401-408.	2.1	90
20	Infliximab for Crohn's Disease: More Than 13 Years of Real-world Experience. <i>Inflammatory Bowel Diseases</i> , 2018, 24, 490-501.	0.9	87
21	Quality of Life After Proctocolectomy With Ileoanal Anastomosis for Patients With Ulcerative Colitis. <i>Journal of Clinical Gastroenterology</i> , 2006, 40, 669-677.	1.1	85
22	Serum 25-hydroxyvitamin D concentration is inversely associated with mucosal inflammation in patients with ulcerative colitis. <i>American Journal of Clinical Nutrition</i> , 2016, 104, 113-120.	2.2	78
23	Safety and Efficacy of Combination Treatment With Calcineurin Inhibitors and Vedolizumab in Patients With Refractory Inflammatory Bowel Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 486-493.	2.4	76
24	Mesalamine delivery systems: do they really make much difference?. <i>Advanced Drug Delivery Reviews</i> , 2005, 57, 281-302.	6.6	73
25	A Comparison of the Quality of Life in Patients with Severe Ulcerative Colitis After Total Colectomy Versus Medical Treatment with Intravenous Cyclosporin. <i>Inflammatory Bowel Diseases</i> , 1999, 5, 1-10.	0.9	67
26	Managing Immunogenic Responses to Infliximab. <i>Drugs</i> , 2004, 64, 1767-1777.	4.9	67
27	Effectiveness of Ustekinumab Dose Escalation in Patients With Crohn's Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 104-110.	2.4	60
28	Clinical guidelines for the medical management of left-sided ulcerative colitis and ulcerative proctitis: Summary statement. <i>Inflammatory Bowel Diseases</i> , 2006, 12, 972-978.	0.9	59
29	Budesonide Multimatrix Is Efficacious for Mesalamine-refractory, Mild to Moderate Ulcerative Colitis: A Randomised, Placebo-controlled Trial. <i>Journal of Crohn's and Colitis</i> , 2017, 11, 785-791.	0.6	57
30	Fecal Calprotectin in Assessing Endoscopic and Histological Remission in Patients with Ulcerative Colitis. <i>Digestive Diseases and Sciences</i> , 2018, 63, 1294-1301.	1.1	53
31	The Use of Vedolizumab in Preventing Postoperative Recurrence of Crohn's Disease. <i>Inflammatory Bowel Diseases</i> , 2018, 24, 502-509.	0.9	50
32	Ustekinumab Is Effective for the Treatment of Chronic Antibiotic-Refractory Pouchitis. <i>Digestive Diseases and Sciences</i> , 2019, 64, 3596-3601.	1.1	50
33	Advances in the management of Crohn's disease: economic and clinical potential of infliximab. <i>Clinical Therapeutics</i> , 1998, 20, 1009-1028.	1.1	49
34	Efficacy and safety of repeated infliximab infusions for Crohn's disease: 1-year clinical experience. <i>Inflammatory Bowel Diseases</i> , 2001, 7, S17-S22.	0.9	47
35	Direct and indirect healthcare resource utilization and costs associated with ulcerative colitis in a privately-insured employed population in the US. <i>Journal of Medical Economics</i> , 2015, 18, 447-456.	1.0	47
36	The Safety Profile of Vedolizumab in Ulcerative Colitis and Crohn's Disease: 4 Years of Global Post-marketing Data. <i>Journal of Crohn's and Colitis</i> , 2020, 14, 192-204.	0.6	45

#	ARTICLE	IF	CITATIONS
37	Effects of fistula on healthcare costs and utilization for patients with Crohn's disease treated in a managed care environment. <i>Inflammatory Bowel Diseases</i> , 2008, 14, 1707-1714.	0.9	39
38	Factors associated with readmission to the hospital within 30 days in patients with inflammatory bowel disease. <i>PLoS ONE</i> , 2017, 12, e0182900.	1.1	39
39	Efficacy and safety of induction therapy with calcineurin inhibitors followed by vedolizumab maintenance in 71 patients with severe steroid-refractory ulcerative colitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 637-643.	1.9	37
40	Differential risk of disease progression between isolated anastomotic ulcers and mild ileal recurrence after ileocolonic resection in patients with Crohn's disease. <i>Gastrointestinal Endoscopy</i> , 2019, 90, 269-275.	0.5	36
41	Systematic Review. <i>Inflammatory Bowel Diseases</i> , 2015, 21, 1719-1736.	0.9	35
42	Vedolizumab as Induction and Maintenance for Inflammatory Bowel Disease: 12-month Effectiveness and Safety. <i>Inflammatory Bowel Diseases</i> , 2018, 24, 849-860.	0.9	34
43	Natalizumab in Crohn's Disease. <i>Inflammatory Bowel Diseases</i> , 2013, 19, 621-626.	0.9	33
44	The Effect of Maternal Peripartum Anti-TNF Use on Infant Immune Response. <i>Digestive Diseases and Sciences</i> , 2016, 61, 1622-1627.	1.1	33
45	Low-Dose Metronidazole is Associated With a Decreased Rate of Endoscopic Recurrence of Crohn's Disease After Ileal Resection: A Retrospective Cohort Study. <i>Journal of Crohn's and Colitis</i> , 2019, 13, 1158-1162.	0.6	30
46	Predictors of adalimumab dose escalation in patients with Crohn's disease at a tertiary referral center. <i>Inflammatory Bowel Diseases</i> , 2012, 18, 10-16.	0.9	29
47	Surveillance of IBD Using High Definition Colonoscopes Does Not Miss Adenocarcinoma in Patients with Low-grade Dysplasia. <i>Inflammatory Bowel Diseases</i> , 2016, 22, 631-637.	0.9	27
48	Assessment of peri-polyp biopsy specimens of flat mucosa in patients with inflammatory bowel disease. <i>Gastrointestinal Endoscopy</i> , 2018, 87, 1304-1309.	0.5	25
49	The Incidence and Predictors of Lupus-like Reaction in Patients with IBD Treated with Anti-TNF Therapies. <i>Inflammatory Bowel Diseases</i> , 2013, 19, 2778-2786.	0.9	24
50	Mucosal Healing Is Associated with Improved Long-term Outcome of Maintenance Therapy with Natalizumab in Crohn's Disease. <i>Inflammatory Bowel Diseases</i> , 2013, 19, 2577-2583.	0.9	24
51	Cyclosporin Therapy After Infliximab Failure in Hospitalized Patients With Acute Severe Colitis is Effective and Safe. <i>Journal of Crohn's and Colitis</i> , 2019, 13, 1105-1110.	0.6	24
52	Nicotine in Ulcerative Colitis. <i>BioDrugs</i> , 1996, 5, 169-174.	0.7	23
53	Crohn's Disease and Takayasu's Arteritis. <i>Journal of Clinical Gastroenterology</i> , 2002, 34, 454-456.	1.1	22
54	Optimizing conventional therapy for inflammatory bowel disease. <i>Current Gastroenterology Reports</i> , 2008, 10, 585-590.	1.1	22

#	ARTICLE	IF	CITATIONS
55	Prevalence of Antibodies Against JC Virus in Patients With Refractory Crohn's Disease and Effects of Natalizumab Therapy. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 1919-1925.	2.4	21
56	Efficacy and Follow-up of Segmental or Subtotal Colectomy in Patients With Colitis-Associated Neoplasia. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 205-206.	2.4	21
57	Age of Diagnosis is Associated with Disease Presentation and Therapeutic Complications in Patients with Crohn's Disease. <i>Inflammatory Bowel Diseases</i> , 2016, 22, 1027-1031.	0.9	20
58	Higher Thioguanine Nucleotide Metabolite Levels are Associated With Better Long-term Outcomes in Patients With Inflammatory Bowel Diseases. <i>Journal of Clinical Gastroenterology</i> , 2018, 52, 537-544.	1.1	20
59	Medical therapy for ulcerative colitis: The state of the art and beyond. <i>Current Gastroenterology Reports</i> , 2004, 6, 488-495.	1.1	19
60	Collagenous Gastritis: An Unusual Association With Profound Weight Loss. <i>Archives of Pathology and Laboratory Medicine</i> , 2004, 128, 229-232.	1.2	19
61	Daily Aspirin Use Does Not Impact Clinical Outcomes in Patients With Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2021, 27, 236-241.	0.9	18
62	A comparison of the quality of life in patients with severe ulcerative colitis after total colectomy versus medical treatment with intravenous cyclosporin. <i>Inflammatory Bowel Diseases</i> , 0, 5, 1-10.	0.9	18
63	Assessment of Variables Associated with Smoking Cessation in Crohn's Disease. <i>Digestive Diseases and Sciences</i> , 2012, 57, 1026-1032.	1.1	17
64	Pharmacoeconomics and quality of life of current and emerging biologic therapies for inflammatory bowel disease. <i>Current Treatment Options in Gastroenterology</i> , 2007, 10, 185-194.	0.3	15
65	Correlation of nuclear morphometry and DNA ploidy in rectal cancer. <i>Diseases of the Colon and Rectum</i> , 1991, 34, 449-454.	0.7	14
66	Evolving medical therapies for ulcerative colitis. <i>Current Gastroenterology Reports</i> , 2002, 4, 497-505.	1.1	14
67	Approach to Optimize Anti-TNF Therapy in Patients With IBD. <i>Current Treatment Options in Gastroenterology</i> , 2016, 14, 83-90.	0.3	14
68	Abnormal Pouchogram Predicts Pouch Failure Even in Asymptomatic Patients. <i>Diseases of the Colon and Rectum</i> , 2019, 62, 463-469.	0.7	14
69	A comparison of the risk of postoperative recurrence between African-American and Caucasian patients with Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 48, 933-940.	1.9	12
70	Fecal Calprotectin Is Highly Effective to Detect Endoscopic Ulcerations in Crohn's Disease Regardless of Disease Location. <i>Inflammatory Bowel Diseases</i> , 2021, 27, 1008-1016.	0.9	12
71	First two patients with ulcerative colitis who developed classical thrombotic thrombocytopenic purpura successfully treated with medical therapy and plasma exchange. <i>Journal of Clinical Apheresis</i> , 2002, 17, 204-206.	0.7	11
72	Incidence and Predictors of Clinical Response, Re-induction Dose, and Maintenance Dose Escalation with Certolizumab Pegol in Crohn's Disease. <i>Inflammatory Bowel Diseases</i> , 2014, 20, 1722-1728.	0.9	11

#	ARTICLE	IF	CITATIONS
73	Immunomodulatory agents and other medical therapies in inflammatory bowel disease. <i>Current Opinion in Gastroenterology</i> , 1995, 11, 321-330.	1.0	10
74	Risk Factors for <i>Clostridium difficile</i> Isolation in Inflammatory Bowel Disease: A Prospective Study. <i>Digestive Diseases and Sciences</i> , 2018, 63, 1016-1024.	1.1	10
75	What to Do When Biologic Agents Are Not Working in Inflammatory Bowel Disease Patients. <i>Gastroenterology and Hepatology</i> , 2015, 11, 657-65.	0.2	10
76	Vedolizumab for perianal fistulizing Crohn's disease: systematic review and meta-analysis. <i>Intestinal Research</i> , 2022, 20, 240-250.	1.0	10
77	Once-daily MMX mesalamine for the treatment of mild-to-moderate ulcerative colitis. <i>Therapeutics and Clinical Risk Management</i> , 2007, 3, 919-27.	0.9	9
78	Evolving medical therapies for ulcerative colitis. <i>Current Gastroenterology Reports</i> , 2001, 3, 464-470.	1.1	8
79	Maintaining remission in ulcerative colitis – role of once daily extended-release mesalamine. <i>Drug Design, Development and Therapy</i> , 2011, 5, 111.	2.0	8
80	Risk factors and treatment outcomes of peristomal pyoderma gangrenosum in patients with inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 1365-1372.	1.9	8
81	The Correlation between Vitamin D Levels and the Risk of Postoperative Recurrence in Crohn's Disease. <i>Digestion</i> , 2021, 102, 767-775.	1.2	8
82	Infliximab decreases resource utilization in patients with Crohn's disease. <i>American Journal of Gastroenterology</i> , 2000, 95, 2499-2500.	0.2	7
83	How should we treat severe acute steroid-refractory ulcerative colitis?. <i>Inflammatory Bowel Diseases</i> , 2009, 15, 150-151.	0.9	7
84	Inpatient Therapy With Calcineurin Inhibitors in Severe Ulcerative Colitis. <i>Inflammatory Bowel Diseases</i> , 2020, 27, 1620-1625.	0.9	7
85	Factors associated with anti-tumor necrosis factor effectiveness to prevent postoperative recurrence in Crohn's disease. <i>Intestinal Research</i> , 2022, 20, 303-312.	1.0	7
86	Outcome of elective switching to vedolizumab in inflammatory bowel disease patients under tumor necrosis factor antagonist—maintained clinical remission. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2019, 34, 2090-2095.	1.4	6
87	Postoperative management of ulcerative colitis and crohn's disease. <i>Current Gastroenterology Reports</i> , 2005, 7, 492-499.	1.1	5
88	Pharmacoeconomic considerations for inflammatory bowel disease in the era of biological therapies. <i>Expert Review of Gastroenterology and Hepatology</i> , 2007, 1, 101-112.	1.4	5
89	IBD: the drugs work...but do the patients?. <i>American Journal of Gastroenterology</i> , 2003, 98, 722-723.	0.2	4
90	Clinical Response and Complications are not Associated with Drug Levels in Patients with Severe Ulcerative Colitis on IV Cyclosporine Induction Therapy. <i>Inflammatory Bowel Diseases</i> , 2018, 24, 1291-1297.	0.9	3

#	ARTICLE	IF	CITATIONS
91	Predictability of simple endoscopic score for Crohn's disease for postoperative outcomes in Crohn's disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 2785-2793.	1.4	3
92	Management of refractory ulcerative colitis. <i>Current Treatment Options in Gastroenterology</i> , 2006, 9, 234-245.	0.3	2
93	Infliximab as First-Line Therapy for Severe Crohn's Disease?. <i>Inflammatory Bowel Diseases</i> , 2002, 8, 58-59.	0.9	1
94	Response:. <i>Gastrointestinal Endoscopy</i> , 2008, 67, 1009-1010.	0.5	1
95	P-074 Age of Diagnosis Is Associated with the Severity of Adverse Effects to Therapy in Crohn's Disease Patients. <i>Inflammatory Bowel Diseases</i> , 2013, 19, S55.	0.9	1
96	Letter: is unrealised adult height resulting from paediatric Crohn's disease associated with a potential reduction in lifetime earnings?. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 559-560.	1.9	1
97	UC CANCERS IN PSC: RIGHT SIDED OR WRONG?. <i>Inflammatory Bowel Diseases</i> , 1998, 4, 330.	0.9	0
98	PREVALENCE, PATTERN, AND PREDICTORS OF ALCOHOL (ETOH) USE FOLLOWING LIVER TRANSPLANTATION (OLT).. <i>Transplantation</i> , 2000, 69, S390.	0.5	0
99	Transcending therapeutic conventions: New realities in the treatment of Crohn's disease. <i>Inflammatory Bowel Diseases</i> , 2001, 7, S1-S1.	0.9	0
100	Direct and Indirect Utilization and Costs Associated With Ulcerative Colitis. <i>Inflammatory Bowel Diseases</i> , 2012, 18, S41.	0.9	0
101	Natalizumab in Crohn's Disease: Results from a U.S. Tertiary IBD Center. <i>American Journal of Gastroenterology</i> , 2012, 107, S672-S673.	0.2	0
102	Nonmedical Switching of Biosimilars in Patients With Inflammatory Bowel Disease. <i>Gastroenterology and Hepatology</i> , 2017, 13, 697-699.	0.2	0
103	A Comprehensive Review of Topical Therapies for Distal Ulcerative Colitis. <i>Gastroenterology and Hepatology</i> , 2020, 16, 21-27.	0.2	0
104	Rare and Well Done: Endoscopic Control of Colonic Hemorrhage in Severe Ulcerative Colitis. <i>Digestive Diseases and Sciences</i> , 2022, 67, 805-809.	1.1	0